Prime Medicine, Inc. (PRME) has released an update.
Prime Medicine, Inc. has struck a deal with top financial institutions for a public offering of over 19 million shares and pre-funded warrants, aiming to raise approximately $150.9 million. The capital is earmarked for research, clinical development, and other corporate expenses, with the transaction set to complete around February 20, 2024. The offering includes an optional purchase of additional shares by the underwriters and allows for warrant exercises through cash or cashless transactions, subject to ownership limitations.
For further insights into PRME stock, check out TipRanks’ Stock Analysis page.
